Last update at 2025-05-23T16:45:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech
Thu 22 May 25, 03:39 PMBAX Stock May Rise Following the Launch of FDA-Approved Hemopatch Pad
Wed 21 May 25, 02:48 PMSYK Stock Likely to Rise Following FDA Clearance for OptaBlate System
Tue 20 May 25, 01:22 PMIs IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?
Wed 14 May 25, 01:40 PMIs Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?
Mon 28 Apr 25, 01:40 PMLFWD Stock Falls Despite Launch of Next-Generation Mobility ReWalk 7
Wed 16 Apr 25, 11:13 AMBreakdown | 2023-05-31 | 2022-05-31 | 2021-05-31 | 2020-05-31 | 2019-05-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-05-31 | 2022-05-31 | 2021-05-31 | 2020-05-31 | 2019-05-31 |
Income before tax | -54.43700M | -29.94900M | -36.05200M | -167.13500M | 59.47M |
Minority interest | - | - | - | - | - |
Net income | -52.44200M | -26.54700M | -31.54800M | -165.78700M | 61.34M |
Selling general administrative | 40.00M | 38.45M | 35.92M | 37.87M | 35.17M |
Selling and marketing expenses | 104.25M | 95.30M | 81.31M | 78.63M | 80.96M |
Gross profit | 174.25M | 165.73M | 156.79M | 150.27M | 191.87M |
Reconciled depreciation | 30.87M | 29.35M | 25.92M | 23.80M | 25.88M |
Ebit | -19.23300M | -19.00700M | -14.87000M | -14.16700M | 72.92M |
Ebitda | 11.64M | 10.34M | 11.05M | 9.64M | 98.80M |
Depreciation and amortization | 30.87M | 29.35M | 25.92M | 23.80M | 25.88M |
Non operating income net other | -0.55400M | -0.79000M | 0.09M | -1.03700M | -5.30600M |
Operating income | -19.23300M | -19.00700M | -14.87000M | -14.16700M | 21.43M |
Other operating expenses | 357.43M | 334.44M | 305.97M | 278.19M | 332.95M |
Interest expense | 2.70M | 0.69M | 0.86M | 0.91M | 5.10M |
Tax provision | -1.99500M | -3.40200M | -4.50400M | -1.34800M | -3.55600M |
Interest income | - | - | - | 0.91M | 5.10M |
Net interest income | -2.70200M | -0.68800M | -0.86100M | -0.90700M | -5.09900M |
Extraordinary items | - | - | - | - | 72.49M |
Non recurring | 32.50M | 10.25M | 20.32M | 153.06M | 8.35M |
Other items | - | - | - | - | - |
Income tax expense | -1.99500M | -3.40200M | -4.50400M | -1.34800M | -1.87100M |
Total revenue | 338.75M | 316.22M | 291.01M | 264.16M | 359.48M |
Total operating expenses | 192.93M | 183.95M | 171.75M | 164.31M | 165.34M |
Cost of revenue | 164.51M | 150.49M | 134.22M | 113.89M | 167.61M |
Total other income expense net | -35.20400M | -10.94200M | -21.18200M | -152.96800M | -13.45000M |
Discontinued operations | - | - | - | - | 72.49M |
Net income from continuing ops | -52.44200M | -26.54700M | -31.54800M | -166.78700M | -11.14600M |
Net income applicable to common shares | -52.44200M | -26.54700M | -31.54800M | -166.78700M | 61.34M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 | 2020-05-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 | 2020-05-31 |
Total assets | 317.67M | 532.64M | 552.75M | 561.44M | 595.51M |
Intangible assets | 77.38M | 111.14M | 152.38M | 168.98M | 197.14M |
Earning assets | - | - | - | - | - |
Other current assets | 12.97M | 4.62M | 2.20M | 1.76M | 2.24M |
Total liab | 112.08M | 154.34M | 128.26M | 121.98M | 139.64M |
Total stockholder equity | 205.59M | 378.30M | 424.49M | 439.46M | 455.87M |
Deferred long term liab | - | 12.81M | 16.04M | 19.95M | 24.06M |
Other current liab | 50.91M | 43.38M | 21.46M | 37.95M | 2.13M |
Common stock | 0.39M | 0.38M | 0.38M | 0.38M | 0.37M |
Capital stock | 0.39M | 0.38M | 0.38M | 0.38M | 0.37M |
Retained earnings | -395.20400M | -210.85500M | -158.41300M | -131.86600M | -100.31800M |
Other liab | - | 17.38M | 24.20M | 37.08M | 39.55M |
Good will | 0.00000M | 159.24M | 201.06M | 201.32M | 201.51M |
Other assets | - | 49.22M | 10.96M | 3.81M | 5.19M |
Cash | 76.06M | 44.62M | 28.82M | 48.16M | 54.44M |
Cash and equivalents | - | - | - | - | - |
Total current liabilities | 91.16M | 83.83M | 74.32M | 57.58M | 51.53M |
Current deferred revenue | - | -14.76100M | 16.04M | - | 29.47M |
Net debt | -71.32800M | 5.20M | 4.96M | -28.16100M | -13.59900M |
Short term debt | 1.98M | 14.76M | 8.78M | - | 0.84M |
Short long term debt | 4.73M | 14.76M | 8.78M | - | 0.84M |
Short long term debt total | 5.91M | 49.82M | 33.78M | 20.00M | 40.84M |
Other stockholder equity | 604.77M | 593.49M | 581.16M | 567.79M | 557.16M |
Property plant equipment | - | 44.38M | 45.01M | 37.07M | 28.31M |
Total current assets | 193.25M | 163.54M | 143.34M | 140.88M | 152.91M |
Long term investments | - | - | - | - | - |
Net tangible assets | - | 378.30M | 71.05M | 69.16M | 57.22M |
Short term investments | - | - | - | - | - |
Net receivables | 43.61M | 52.83M | 52.30M | 35.41M | 31.26M |
Long term debt | - | 49.82M | 25.00M | 20.00M | 40.00M |
Inventory | 60.62M | 55.33M | 51.39M | 48.61M | 59.91M |
Accounts payable | 37.75M | 40.45M | 28.05M | 19.63M | 19.10M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | - | - | - | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | -4.36500M | -4.72300M | 1.36M | 3.15M | -1.34100M |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | - | 0.38M | 0.38M | 0.38M | 0.37M |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | - | -210.85500M | -158.41300M | -131.86600M | -100.31800M |
Treasury stock | - | -5.71400M | -5.71400M | -5.71400M | -5.71400M |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | 5.57M | 54.33M | -5.07400M | 13.19M | 15.64M |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 124.42M | 369.10M | 409.41M | 420.56M | 442.60M |
Capital lease obligations | - | - | - | - | - |
Long term debt total | - | 49.82M | 25.00M | 20.00M | 40.00M |
Breakdown | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 | 2020-05-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 | 2020-05-31 |
Investments | 123.72M | -9.74600M | -11.41000M | -8.52400M | -63.34500M |
Change to liabilities | - | 2.14M | 3.91M | 4.88M | -15.46700M |
Total cashflows from investing activities | - | -9.74600M | -19.30700M | -13.71100M | -63.34500M |
Net borrowings | - | 24.25M | 5.00M | -20.00000M | -93.27500M |
Total cash from financing activities | -64.24800M | 25.42M | 7.68M | -16.98600M | -95.24200M |
Change to operating activities | - | 0.33M | -5.01200M | -3.18100M | -6.15500M |
Net income | -184.34900M | -52.44200M | -26.54700M | -31.54800M | -165.78700M |
Change in cash | 31.44M | 15.79M | -19.33600M | -6.27400M | -173.20600M |
Begin period cash flow | 44.62M | 28.82M | 48.16M | 54.44M | 227.64M |
End period cash flow | 76.06M | 44.62M | 28.82M | 48.16M | 54.44M |
Total cash from operating activities | -28.15800M | 0.08M | -7.19400M | 24.09M | -14.55400M |
Issuance of capital stock | - | - | - | - | - |
Depreciation | 27.71M | 30.87M | 29.35M | 25.92M | 23.80M |
Other cashflows from investing activities | - | -5.93400M | -15.01000M | -8.52400M | -56.11000M |
Dividends paid | - | - | - | - | - |
Change to inventory | -9.41000M | -8.19800M | -2.79600M | 11.54M | -18.84500M |
Change to account receivables | 7.89M | -1.29900M | -17.15100M | -4.16200M | 11.92M |
Sale purchase of stock | - | - | - | - | -0.75900M |
Other cashflows from financing activities | -15.00000M | 0.42M | 2.68M | -13.71100M | 38.02M |
Change to netincome | - | 28.50M | 11.05M | 23.00M | 156.47M |
Capital expenditures | 5.77M | 4.35M | 4.30M | 13.71M | 7.58M |
Change receivables | - | -1.29900M | -17.15100M | -4.16200M | 11.92M |
Cash flows other operating | - | 0.51M | -6.28100M | -5.53000M | -5.65300M |
Exchange rate changes | - | - | - | 0.33M | -0.06500M |
Cash and cash equivalents changes | - | 15.75M | -18.81800M | -6.27400M | -173.20600M |
Change in working capital | 14.42M | -7.02600M | -21.04700M | 9.07M | -28.54900M |
Stock based compensation | 10.53M | 11.16M | 10.69M | 8.62M | 7.59M |
Other non cash items | 111.50M | 19.82M | 4.07M | 16.83M | 149.95M |
Free cash flow | -33.92600M | -4.27400M | -11.49100M | 10.38M | -22.13900M |
Sector: Healthcare Industry: Medical Instruments & Supplies
Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
ANGO AngioDynamics Inc |
-0.21 2.23% | 9.20 | - | 96.15 | 1.23 | 1.78 | 1.03 | -137.629 |
ISRG Intuitive Surgical Inc |
-2.37 0.44% | 540.30 | 73.05 | 61.73 | 19.15 | 10.25 | 18.41 | 59.92 |
ESLOY Essilor International SA |
-6.24 4.21% | 141.86 | 35.39 | 24.81 | 3.63 | 2.20 | 4.00 | 16.25 |
ESLOF EssilorLuxottica Société anonyme |
-8.81 3.04% | 281.19 | 35.71 | 25.13 | 3.62 | 2.23 | 4.00 | 16.25 |
BDX Becton Dickinson and Company |
-1.88 1.09% | 170.43 | 37.72 | 15.92 | 3.25 | 2.49 | 4.08 | 17.10 |
AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.
14 Plaza Drive, Latham, NY, United States, 12110
Name | Title | Year Born |
---|---|---|
Mr. James C. Clemmer | CEO, Pres & Director | 1964 |
Mr. Stephen A. Trowbridge | Exec. VP & CFO | 1974 |
Mr. David D. Helsel | Sr. VP of Global Operations and R&D | 1964 |
Mr. Chad T. Campbell | Sr. VP & GM of Vascular Access Global Bus. Unit | 1971 |
Ms. Laura Piccinini | Sr. VP & GM of International | 1970 |
Mr. Richard C. Rosenzweig | Sr. VP, Gen. Counsel & Company Sec. | 1967 |
Mr. Benjamin H. Davis | Sr. VP of Bus. Devel. | 1964 |
Ms. Marna I. Bronfen-Moore | Sr. VP of HR | 1967 |
Mr. Warren G. Nighan | Sr. VP of Quality & Regulatory Affairs | 1969 |
Ms. Kim L. Seabury | Sr. VP of Information Technology | 1967 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.